European Urology Open Science最新文献

{"title":"Integration of Darolutamide in the Treatment Landscape for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis of Efficacy and Safety","authors":"Felix Melchior ,&nbsp;Magdalena Koett ,&nbsp;Felix Keller ,&nbsp;Nastasiia Artamonova ,&nbsp;Giulia Giannini ,&nbsp;Mona Kafka ,&nbsp;Michael Ladurner ,&nbsp;Hannes Neuwirt ,&nbsp;Jasmin Bektic ,&nbsp;Wolfgang Horninger ,&nbsp;Isabel Heidegger","doi":"10.1016/j.euros.2025.11.011","DOIUrl":"10.1016/j.euros.2025.11.011","url":null,"abstract":"<div><h3>Background and objective</h3><div>Recent advances have led to the introduction of multiple combination treatments for metastatic hormone-sensitive prostate cancer (mHSPC), but their comparative efficacy and toxicity remain uncertain owing to the absence of head-to-head comparisons. We evaluated the efficacy and safety profile of darolutamide plus androgen deprivation therapy (ADT) in comparison to other treatments.</div></div><div><h3>Methods</h3><div>A systematic search was conducted in the Cochrane Library up to September 30, 2024 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Hazard ratios (HRs) and confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were extracted. Odds ratios (ORs) for treatment-emergent adverse events (TEAEs) were calculated from the events reported.</div></div><div><h3>Key findings and limitations</h3><div>Eleven trials involving 11 389 patients were included. Darolutamide triplet therapy was associated with the highest overall PFS (HR 0.24, 95% CI 0.20–0.29) and OS (HR 0.54, 95% CI 0.44–0.66). The highest PFS in low-volume disease was observed with enzalutamide (HR 0.29, 95% CI 0.21–0.38) and darolutamide (HR 0.30, 95% CI 0.15–0.60). All androgen receptor pathway inhibitors (ARPIs) had higher toxicity than ADT, except for darolutamide (OR 0.99, 95% CI 0.71–1.39). In comparison to darolutamide, enzalutamide (OR 2.03, 95% CI 1.08–3.80) and abiraterone (OR 3.18, 95% CI 1.74–5.80) were associated with higher risk of hypertension. Enzalutamide was associated with a higher risk of fatigue (OR 3.22, 95% CI 1.28–8.07). Limited direct comparisons between treatments may affect our conclusions regarding relative efficacy.</div></div><div><h3>Conclusions and clinical implications</h3><div>Our findings support the role of darolutamide as an effective and well-tolerated ARPI for mHSPC, particularly in low-volume metachronous disease and comorbidity-limited cases. These results may assist clinicians in planning personalized treatment strategies that balance efficacy and safety.</div></div><div><h3>Patient summary</h3><div>We compared different medical treatment options for metastatic hormone-sensitive prostate cancer, with a special focus on a drug called darolutamide. Darolutamide is well tolerated and is effective, particularly in patients with a low volume of metastasis and patients with other health conditions that may limit their treatment options.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"83 ","pages":"Pages 72-82"},"PeriodicalIF":4.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alterations in the Cerebral Perivascular Space Network as a Potential Central Mechanism in Overactive Bladder: A Neuroimaging-Clinical Association Study","authors":"Ye Hua ,&nbsp;Yuwei Zhang ,&nbsp;Feng Lu ,&nbsp;Yuhua Zhou ,&nbsp;Huihui Song ,&nbsp;Deshui Yu ,&nbsp;Kaixin Zhang ,&nbsp;Qian Liu ,&nbsp;Kaiyuan Gu ,&nbsp;Tianyi Zhu ,&nbsp;Siyi Fu ,&nbsp;Yong-Jie Lu ,&nbsp;Yi Fan ,&nbsp;Ninghan Feng","doi":"10.1016/j.euros.2025.11.007","DOIUrl":"10.1016/j.euros.2025.11.007","url":null,"abstract":"<div><h3>Background and objective</h3><div>The role of the central nervous system (CNS) in overactive bladder (OAB) is not completely understood. Our aim was to investigate the association between alterations in the brain perivascular network and OAB, and to identify potential biomarkers for future intervention trials.</div></div><div><h3>Methods</h3><div>This prospective study included 131 patients with OAB and 119 healthy individuals matched for age, sex, and education. High-resolution 3.0-T magnetic resonance imaging was used to measure brain glymphatic system (BGS) markers, including white matter (WM) and subcortical perivascular space (PVS) characteristics, the free water (FW) fraction, the Analysis Along the Perivascular Space index, and the choroid plexus volume. Spearman and partial correlation analyses were used to examine relationships between imaging results and clinical data. Linear regression and partial correlation analyses for 6-mo follow-up data were conducted to assess longitudinal associations between changes in BGS parameters and OAB symptom progression.</div></div><div><h3>Key findings and limitations</h3><div>Patients with OAB exhibited notable BGS alterations, among which the WM-PVS count and FW fraction were strongly associated with clinical questionnaire scores. At 6-mo follow-up, progression of OAB symptoms was linked to a significant increase in brain FW content. However, we did not systematically evaluate how bladder function is related to changes in specific brain regions.</div></div><div><h3>Conclusions and clinical implications</h3><div>This study reveals for the first time an association between BGS dysfunction and OAB symptom severity. Our findings reinforce the role of the CNS in contributing to OAB and highlight potential therapeutic targets.</div></div><div><h3>Patient summary</h3><div>We used MRI (magnetic resonance imaging) brain scans and questionnaires on overactive bladder (OAB) symptoms to look at possible links between brain changes and OAB. Our results suggest that changes within the brain network may be a central mechanism in OAB. This new discovery may help in the development of new treatments for patients with OAB.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"83 ","pages":"Pages 46-53"},"PeriodicalIF":4.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate Cancer Risk and DNA Mismatch Repair Deficiency Among Lynch Syndrome Patients","authors":"Linda Rodgers-Fouché ,&nbsp;Nick A. Kamkari ,&nbsp;Melany Cruz ,&nbsp;Andrew Gusev ,&nbsp;Sara I. Justiniano ,&nbsp;Chin-Lee Wu ,&nbsp;Daniel C. Chung ,&nbsp;Keyan Salari","doi":"10.1016/j.euros.2025.11.006","DOIUrl":"10.1016/j.euros.2025.11.006","url":null,"abstract":"<div><h3>Background and objective</h3><div>Lynch syndrome (LS) increases the risk of gastrointestinal, endometrial, and other cancers. Recent data suggest that LS also increases the risk of prostate cancer (PC). Our study aims to characterize the incidence and the clinical and molecular features of PC in LS.</div></div><div><h3>Methods</h3><div>Adult males with LS were identified from an institutional genetic testing registry. PC diagnoses were identified, and tumor tissue was assessed for DNA mismatch repair deficiency (dMMR) by immunohistochemistry.</div></div><div><h3>Key findings and limitations</h3><div>Among 235 adult males with LS, 35 were diagnosed with PC at a median age of 60 yr (interquartile range: 58–69.5). By age 75 yr, the cumulative incidence of any PC and clinically significant PC was 38% (95% confidence interval [CI]: 27–50%) and 26% (95% CI: 16–37%), respectively. MMR deficiency was observed in 75% of tumors from <em>MSH2/EPCAM</em> pathogenic variant (PV) carriers and in 20% from <em>MSH6</em> PV carriers; no dMMR tumors were observed in <em>MLH1</em> or <em>PMS2</em> PV carriers. The majority (71%) of patients with unfavorable intermediate- or higher-risk disease had dMMR tumors, while none with lower-risk disease had dMMR tumors (<em>p</em> &lt; 0.001). LS patients with a family history of PC were three times more likely to develop the disease (26% vs 10%, odds ratio 3.00, <em>p</em> &lt; 0.001) than those without a family history. This study was limited by the number of cases at one institution.</div></div><div><h3>Conclusions and clinical implications</h3><div>MMR-deficient PC was significantly associated with higher-risk clinicopathological features, suggesting that MMR testing should be considered for LS patients with PC to help inform clinical management. Additionally, these data support special consideration of PC screening among LS patients with <em>MSH2, EPCAM</em>, or <em>MSH6</em> PV, and/or a family history of PC.</div></div><div><h3>Patient summary</h3><div>In this study, we looked at the incidence and characteristics of prostate cancer that develops among individuals with Lynch syndrome. We found that individuals with Lynch syndrome have an elevated risk of developing prostate cancer, but this risk varied by Lynch syndrome gene and family history. This information will help guide targeted prostate cancer screening and management for individuals with Lynch syndrome.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"83 ","pages":"Pages 83-90"},"PeriodicalIF":4.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Survival of Midurethral Mesh Slings for Women with Stress Urinary Incontinence","authors":"Margaux Laude ,&nbsp;Imad Bentellis ,&nbsp;Roxane Fabre ,&nbsp;Matthieu Durand ,&nbsp;Brannwel Tibi ,&nbsp;Céline Chauleur ,&nbsp;Benoit Peyronnet ,&nbsp;Laurent Bailly","doi":"10.1016/j.euros.2025.11.012","DOIUrl":"10.1016/j.euros.2025.11.012","url":null,"abstract":"<div><h3>Background and objective</h3><div>Midurethral sling (MUS) use for stress urinary incontinence (SUI) has declined because of controversies. However, there is little evidence on the long-term prevalence of MUS reoperation. The aim of this study was to examine long-term removal and reoperation rates among women with MUS.</div></div><div><h3>Methods</h3><div>This national retrospective cohort study included all female patients aged ≥18 yr with a first MUS insertion for SUI in all French public hospitals and private practices between January 1, 2013, and September 30, 2022. Patients were followed until January 1, 2023. The primary outcome was the MUS removal rate. Secondary outcomes were new MUS insertion and any other surgery for SUI. Cox regression models were used to assess potential factors associated with MUS removal.</div></div><div><h3>Key findings and limitations</h3><div>The study included 217 326 women with a first MUS insertion. There were 5851 MUS removals and 9521 new MUS insertions. Most removals occurred within the first year (58%). The MUS removal rate was 2.7% at 10 yr. There were fewer removals after transoboturator insertion than after retropubic insertion. Alcohol consumption, smoking, and obesity were associated with MUS reoperation. At 10 yr, the rate of new MUS insertions was 4.5% and the rate of any other surgeries was 2.8%.</div></div><div><h3>Conclusions and clinical implications</h3><div>These findings may help in counseling patients on decision-making for SUI treatment.</div></div><div><h3>Patient summary</h3><div>One treatment option for stress urinary incontinence (SUI) in women is insertion of a mesh sling. We looked at the rates of sling removal and reoperation among women treated for SUI in the French population. We found that after 10 years, only 2.7% of cases needed sling removal, 4.5% needed a new sling inserted without removal of the previous sling, and 2.8% needed another type of surgery. These results will help patients in choosing the correct treatment for SUI.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"83 ","pages":"Pages 91-98"},"PeriodicalIF":4.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Chemotherapy Prior to Trimodality Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis","authors":"Keiichiro Miyajima ,&nbsp;Akihiro Matsukawa ,&nbsp;Takafumi Yanagisawa ,&nbsp;Marcin Miszczyk ,&nbsp;Navid Roessler ,&nbsp;Shota Inoue ,&nbsp;Abdulrahman S. Alqahtani ,&nbsp;Ahmed R. Alfarhan ,&nbsp;Fumihiko Urabe ,&nbsp;Keiichiro Mori ,&nbsp;Pierre I. Karakiewicz ,&nbsp;Takahiro Kimura ,&nbsp;Shahrokh F. Shariat","doi":"10.1016/j.euros.2025.11.005","DOIUrl":"10.1016/j.euros.2025.11.005","url":null,"abstract":"<div><h3>Background and objective</h3><div>Neoadjuvant chemotherapy (NACT) before radical cystectomy improves outcomes in muscle-invasive bladder cancer (MIBC), but its value before trimodality therapy (TMT; maximal transurethral resection of the bladder tumor plus concurrent chemoradiation) is uncertain. This review aims to evaluate whether the addition of NACT to TMT is associated with improved survival in patients with MIBC.</div></div><div><h3>Methods</h3><div>We systematically searched the MEDLINE, Embase, and Web of Science databases (February 2025). Eligible studies reported adjusted estimates for overall (OS), cancer-specific (CSS), or disease-free (DFS)/recurrence-free survival in patients undergoing TMT, comparing those who received versus those who did not receive NACT. Random-effect meta-analyses pooled multivariable hazard ratios (HRs). The risk of bias was assessed with ROBINS-I (PROSPERO registration: CRD420251120157).</div></div><div><h3>Key findings and limitations</h3><div>Fourteen studies comprising 4112 patients met the inclusion criteria. However, only two to three studies contributed adjusted HRs for each oncological outcome regarding the use of NACT or the response to NACT. Gemcitabine-cisplatin was the most common NACT regimen (reported in ten studies). Compared with no NACT, NACT was not associated with a statistically significant improvement in OS (HR 0.93, 95% confidence interval [CI] 0.78–1.12, <em>p</em> = 0.40; three studies, <em>n</em> = 3500) or CSS (HR 0.76, 95% CI 0.51–1.12; <em>p</em> = 0.16; two studies, <em>n</em> = 934). Among patients who received NACT, clinical/pathological response was associated with better outcomes (OS: HR 0.26, 95% CI 0.08–0.86, <em>p</em> = 0.03; two studies, <em>n</em> = 74; DFS: HR 0.42, 95% CI 0.25–0.70, <em>p</em> &lt; 0.001; two studies, <em>n</em> = 116). Overall certainty is limited by nonrandomized design, heterogeneity in patient selection, TMT protocols and response definitions, and the modest number of adjusted studies.</div></div><div><h3>Conclusions and clinical implications</h3><div>Across adjusted observational data, addition of NACT before TMT was not associated with a survival benefit. However, patients who respond to NACT experience a substantially better prognosis. Prospective trials testing modern neoadjuvant strategies—particularly immunotherapy- and targeted therapy-based regimens—within the standardized TMT protocols are warranted.</div></div><div><h3>Patient summary</h3><div>We reviewed studies in which chemotherapy was given before a bladder-sparing approach, called trimodality therapy (tumor removal plus chemoradiation). Overall, this treatment approach did not improve survival, although patients who responded to the pretreatment did better. Newer drugs, including immunotherapy, should be tested in this setting.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"83 ","pages":"Pages 54-63"},"PeriodicalIF":4.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder Cancer Burden in the USA: Population Scenarios for 2040","authors":"Hawre Jalal ,&nbsp;Stella K. Kang ,&nbsp;Fernando Alarid-Escudero ,&nbsp;Stavroula A. Chrysanthopoulou ,&nbsp;David Ulises Garibay-Trevino ,&nbsp;Bruce L. Jacobs ,&nbsp;Karen M. Kuntz ,&nbsp;Praveen Kumar ,&nbsp;Jonah H. Popp ,&nbsp;Yuliia Sereda ,&nbsp;Mutita Siriruchatanon ,&nbsp;John B. Wong ,&nbsp;Thomas A. Trikalinos ,&nbsp;the CISNET Bladder Cancer Modeling Investigators","doi":"10.1016/j.euros.2025.11.013","DOIUrl":"10.1016/j.euros.2025.11.013","url":null,"abstract":"<div><h3>Background and objective</h3><div>Bladder cancer is the sixth most common cancer among men and is expensive to manage. We independently developed three microsimulation models that describe its natural history and explain epidemiological trends. We projected bladder cancer burden in the USA through 2040 to inform workforce planning.</div></div><div><h3>Methods</h3><div>We calibrated the models to the Surveillance, Epidemiology and End Results (SEER) program incidence data and standardized key inputs. For White men, the highest-incidence subgroup, the models inferred unobservable epidemiological metrics, including lifetime risks by birth cohort and ages of the key events in the natural history. We simulated individual life histories under calibrated parameter sets and summarized the outcomes as yearly rates and counts.</div></div><div><h3>Key findings and limitations</h3><div>Each model’s predictions reproduced SEER age- and stage-specific incidence data. Across models, the lifetime risk of bladder cancer grew from approximately 1.5–2.4% in the 1910 to 3.1–4.4% in the 2010 birth cohorts, consistent with longevity and smoking exposure patterns. Of the cancer cases, 75% instantiate after ages 61–64 yr. The median model durations from when a cancer is screen detectable to its clinical manifestation were 2.1–3.3 yr, with a wide range across individuals. Through 2040, the incidence standardized to the 2000 US population declined by 0.4–0.6%/yr (consistent with the declining smoking rates, the most important environmental risk factor), but the annual incidence and new cases increased by 1.5–1.8%/yr (because the baby boomer population is living longer). Modeling supplements incomplete data with assumptions, but similar findings across independent models suggest some robustness to assumptions.</div></div><div><h3>Conclusions and clinical implications</h3><div>Projected cohort longevity and smoking patterns imply an increased disease burden in the future, which may benefit from commensurate increased research and resources. From the inferred natural history, we speculate a theoretical opportunity for screening, which should be investigated with dedicated modeling and empirical studies.</div></div><div><h3>Patient summary</h3><div>Three computer simulation models predicted the future incidence of bladder cancer burden in White men, in whom this cancer is most common. The models found that although the future incidence of bladder cancer would decrease slightly over time (consistent with the declining smoking rates, the most important environmental risk factor), the overall disease burden increased because the baby boomer population is living longer.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"83 ","pages":"Pages 99-108"},"PeriodicalIF":4.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining the Standard of Care in Fournier’s Gangrene—An Umbrella Review","authors":"Charlotte Müssgens ,&nbsp;Laura Wimmer ,&nbsp;Christian Daniel Fankhauser ,&nbsp;Laila Schneidewind ,&nbsp;Fabian Joel Aschwanden","doi":"10.1016/j.euros.2025.11.009","DOIUrl":"10.1016/j.euros.2025.11.009","url":null,"abstract":"<div><h3>Background and objective</h3><div>Fournier’s gangrene (FG) is a life-threatening bacterial infection. Unfortunately, outcomes have not improved in recent years mainly due to the fact that robust research is challenging in this very rare disease. Consequently, we conducted an umbrella review regarding the standard of care for FG to provide best evidence for clinicians and identify research gaps to plan high-quality studies.</div></div><div><h3>Methods</h3><div>The recommendations provided in the <em>Cochrane Handbook of Systematic Reviews</em> and the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines were followed. The full review protocol was pre-registered and is available at PROSPERO (CRD 42023489596).</div></div><div><h3>Key findings and limitations</h3><div>The primary literature search yielded 3366 references. Finally, we were able to include seven systematic reviews including two meta-analyses. Up to 40% of patients may initially lack cutaneous signs, risking a diagnostic delay and progression to high-mortality disease. Diabetes mellitus emerged as the most prevalent comorbidity across the reviews (32–66%) and was most frequent among nonsurvivors. The management of FG is consistently described as a multimodal emergency, centered on three core interventions: early surgical debridement, empiric broad-spectrum antibiotics, and intensive supportive care. Adjunct interventions need further evaluation. Despite advances in multimodal care, FG carries high mortality and morbidity. There is only moderate confidence mainly due to the risk of bias from the individual studies being included in the reviews.</div></div><div><h3>Conclusions and clinical implications</h3><div>Across the seven reviews, FG remains a life-threatening condition with substantial mortality. Further comprehensive research is needed desperately; a prospective registry might be suitable for managing this rare disease.</div></div><div><h3>Patient summary</h3><div>We conducted an umbrella review, a review including only systematic reviews and meta-analyses, about the standard of care for Fournier’s gangrene (FG), which is a life-threatening and rare bacterial infection, and the clinical outcomes have not improved in recent years. In summary, FG is consistently described as a multimodal emergency, centered on three core interventions: early surgical debridement, empiric broad-spectrum antibiotics, and intensive supportive care; however, despite advances in care, FG is still associated with high mortality and morbidity. Consequently, further robust research is needed.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"83 ","pages":"Pages 64-71"},"PeriodicalIF":4.5,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reassessing patient selection for NeuroSAFE: Biochemical recurrence risk in high-risk prostate cancer patients undergoing robot-assisted radical prostatectomy","authors":"Van Der Poel H.G.,&nbsp;van der Graaf S.,&nbsp;van den Bergh R.,&nbsp;Montfoort M.,&nbsp;Nieuwenhuijsen J.,&nbsp;Vis A.,&nbsp;Roeleveld T.,&nbsp;Wit E.,&nbsp;van leeuwen P.","doi":"10.1016/S2666-1683(25)02525-X","DOIUrl":"10.1016/S2666-1683(25)02525-X","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"82 ","pages":"Page S31"},"PeriodicalIF":4.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune and metabolic rewiring through fasting mimicking diet in localized prostate cancer","authors":"Artamonova N.,&nbsp;Höller A.,&nbsp;Pichler U.,&nbsp;Trebo M.,&nbsp;Nagl L.,&nbsp;Guastadisegni M.,&nbsp;Sopper S.,&nbsp;Salcher S.,&nbsp;Ormanns S.,&nbsp;Eder I.E.,&nbsp;Puhr M.,&nbsp;Pircher A.,&nbsp;Heidegger I.","doi":"10.1016/S2666-1683(25)02500-5","DOIUrl":"10.1016/S2666-1683(25)02500-5","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"82 ","pages":"Page S1"},"PeriodicalIF":4.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCBase Xtend, nationwide, population-based cohort of all men in Sweden with PSA, prostate biopsies, MRI prostate, and use of chemotherapy","authors":"Stattin P.,&nbsp;Westerberg M.,&nbsp;Garmo H.,&nbsp;Holm L.,&nbsp;Gedeborg R.","doi":"10.1016/S2666-1683(25)02520-0","DOIUrl":"10.1016/S2666-1683(25)02520-0","url":null,"abstract":"","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"82 ","pages":"Pages S25-S26"},"PeriodicalIF":4.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}